MedTrace Logo

Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

NCT05078775 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-07-18

No results posted yet for this study

Summary

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.

Conditions

  • Metastatic Pancreatic Adenocarcinoma
  • Locally Advanced Unresectable Pancreatic Adenocarcinoma

Interventions

OTHER

NEAAR Medical Food

Standardized non-essential amino acid restricted medical food.

Sponsors & Collaborators

  • Faeth Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andrew Hendifar, MD · Cedars-Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2025-07-10
Completion
2025-07-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05078775 on ClinicalTrials.gov